# Special Issue

## Toxins as Marine-Based Drug Discovery

### Message from the Guest Editor

Marine organisms have evolved the most sophisticated peptide chemistry and neuropharmacology for their own biological purposes by producing a structural and functional diversity of neurotoxins. These neurotoxins have shown to be highly selective ligands for a wide range of ion channels and receptors. Therefore, they represent interesting lead compounds for the development of, for example, analgesics, anti-cancer drugs, and drugs for neurological disorders, such as multiple sclerosis, Parkinson disease, Alzheimer disease, *etc*. This Special Issue of *Marine Drugs* aims to provide a comprehensive look at marine toxins and toxin inspired leads and will focus on the mechanism of action and structure-function of marine neurotoxins and their targets, including but not limited to, recent developments relating to the emergence of marine organisms as an underutilized source of highly evolved bioactive peptides and small molecules with clinical potential. As , I invite colleagues working on marine bioactive peptides and compounds to contribute to this Special Issue of *Marine Drugs* with interesting papers showing significant advances within this field.

### Guest Editor

Dr. Steve Peigneur

Toxicology and Pharmacology, Department Pharmaceutical Sciences, Catholic University Leuven, Herestraat 49 Box 922, 3000 Leuven, Belgium

### Deadline for manuscript submissions

closed (20 November 2019)

**Marine Drugs**

**an Open Access Journal by MDPI**

**Impact Factor 4.9**
**CiteScore 9.6**
**Indexed in PubMed**

mdpi.com/si/16259

*Marine Drugs*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

mdpi.com/journal/marinedrugs

# Marine Drugs

an Open Access Journal by MDPI

Impact Factor 4.9
CiteScore 9.6
Indexed in PubMed

mdpi.com/journal/marinedrugs

# About the Journal

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

**Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

MDPI